Physician profile
Mary D Collier
NPI 1225019375
$2,275.36
in general payments reported to CMS, 2019-2025
12 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $246 · 2021: $280 · 2022: $163 · 2023: $494 · 2024: $320 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641 · Debt Forgiveness: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.22 |
| Debt Forgiveness | $462.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,192.59 | 2019-2025 | Via Matrix, Novachor, Affinity |
| Djo, LLC | $462.16 | 2023 | |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $109.85 | 2019-2022 | |
| Tactile Systems Technology INC | $98.09 | 2019 | |
| Smith+Nephew, INC. | $63.01 | 2019-2025 | Collagenase Santyl, Regranex |
| Paratek Pharmaceuticals, INC. | $56.34 | 2022-2025 | Nuzyra |
| Nevro Corp. | $48.62 | 2022-2023 | Senza |
| Averitas Pharma INC. | $41.48 | 2024 | Qutenza |
| Grt US Holding, INC. | $33.75 | 2021 | |
| Wright Medical Technology, INC. | $30.52 | 2020 | |
| Bioventus LLC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.